CN113142573A - 一种降糖、脂、血粘的纯天然植物压片糖果及其制备方法 - Google Patents
一种降糖、脂、血粘的纯天然植物压片糖果及其制备方法 Download PDFInfo
- Publication number
- CN113142573A CN113142573A CN202110530298.7A CN202110530298A CN113142573A CN 113142573 A CN113142573 A CN 113142573A CN 202110530298 A CN202110530298 A CN 202110530298A CN 113142573 A CN113142573 A CN 113142573A
- Authority
- CN
- China
- Prior art keywords
- blood
- reducing
- sugar
- lipid
- cinnamon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000009508 confectionery Nutrition 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title description 6
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 35
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 35
- 244000285774 Cyperus esculentus Species 0.000 claims abstract description 28
- 235000005853 Cyperus esculentus Nutrition 0.000 claims abstract description 28
- 241000196324 Embryophyta Species 0.000 claims abstract description 27
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 claims abstract description 15
- 241000388430 Tara Species 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims description 14
- 235000013399 edible fruits Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 235000008730 Ficus carica Nutrition 0.000 claims description 3
- 244000025361 Ficus carica Species 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 58
- 239000008280 blood Substances 0.000 abstract description 58
- 235000000346 sugar Nutrition 0.000 abstract description 22
- 230000001603 reducing effect Effects 0.000 abstract description 21
- 230000006870 function Effects 0.000 abstract description 15
- 230000001105 regulatory effect Effects 0.000 abstract description 13
- 235000013305 food Nutrition 0.000 abstract description 11
- 210000002784 stomach Anatomy 0.000 abstract description 7
- 210000000936 intestine Anatomy 0.000 abstract description 3
- 230000001276 controlling effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 239000000843 powder Substances 0.000 description 22
- 239000000203 mixture Substances 0.000 description 19
- 239000003921 oil Substances 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 206010020772 Hypertension Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 229960004580 glibenclamide Drugs 0.000 description 9
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 7
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 7
- 229940117916 cinnamic aldehyde Drugs 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 235000002961 Aloe barbadensis Nutrition 0.000 description 6
- 244000144927 Aloe barbadensis Species 0.000 description 6
- 244000302512 Momordica charantia Species 0.000 description 6
- 235000009811 Momordica charantia Nutrition 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 235000011399 aloe vera Nutrition 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- 244000037364 Cinnamomum aromaticum Species 0.000 description 5
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 3
- 208000031975 Yang Deficiency Diseases 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 239000002221 antipyretic Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008157 edible vegetable oil Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 235000021313 oleic acid Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- XPDORSROGAZEGY-UHFFFAOYSA-N 4-Methoxybenzyl formate Chemical compound COC1=CC=C(COC=O)C=C1 XPDORSROGAZEGY-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 235000008227 Illicium verum Nutrition 0.000 description 2
- 240000007232 Illicium verum Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241000158728 Meliaceae Species 0.000 description 2
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 2
- 235000018365 Momordica dioica Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 235000019083 Osmanthus fragrans Nutrition 0.000 description 2
- 244000242564 Osmanthus fragrans Species 0.000 description 2
- 235000012550 Pimpinella anisum Nutrition 0.000 description 2
- 240000004760 Pimpinella anisum Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 244000186561 Swietenia macrophylla Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002082 anti-convulsion Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- -1 flavonoid compounds Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000004223 radioprotective effect Effects 0.000 description 2
- 229940080321 sodium anisate Drugs 0.000 description 2
- AETSDHMVQHOYPB-UHFFFAOYSA-M sodium;4-methoxybenzoate Chemical compound [Na+].COC1=CC=C(C([O-])=O)C=C1 AETSDHMVQHOYPB-UHFFFAOYSA-M 0.000 description 2
- 239000010676 star anise oil Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- IZVFFXVYBHFIHY-UHFFFAOYSA-N (3alpha, 5alpha)-Cholest-7-en-3-ol, 9CI Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CCC21 IZVFFXVYBHFIHY-UHFFFAOYSA-N 0.000 description 1
- SEXXGJVBJDNZII-XKUXXBAGSA-N (6r)-6-[(9r,10s,13r,14r,17r)-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-1-ol Chemical compound C1CCC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(CO)C)CC[C@H]33)C)C3=CCC21 SEXXGJVBJDNZII-XKUXXBAGSA-N 0.000 description 1
- KKSCKZFKHNHGEO-UHFFFAOYSA-N 24-methylenecycloartanol Natural products CC(CCC(=C)C(C)(C)O)C1CCC2C3CCC4C(C)(C)C(O)CCC45CC35CCC12C KKSCKZFKHNHGEO-UHFFFAOYSA-N 0.000 description 1
- ZCJRGONXXDDVLB-UHFFFAOYSA-N 28-Isofucosterolacetat Natural products CC=C(CCC(C)C1CCC2C3CCC4CC(CCC4(C)C3CCC12C)OC(=O)C)/C(C)C ZCJRGONXXDDVLB-UHFFFAOYSA-N 0.000 description 1
- XZEUYTKSAYNYPK-UHFFFAOYSA-N 3beta-29-Norcycloart-24-en-3-ol Natural products C1CC2(C)C(C(CCC=C(C)C)C)CCC2(C)C2CCC3C(C)C(O)CCC33C21C3 XZEUYTKSAYNYPK-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 244000160089 Crataegus cuneata Species 0.000 description 1
- 235000008440 Crataegus cuneata Nutrition 0.000 description 1
- 235000014283 Crataegus pinnatifida var major Nutrition 0.000 description 1
- RRTBTJPVUGMUNR-UHFFFAOYSA-N Cycloartanol Natural products C12CCC(C(C(O)CC3)(C)C)C3C2(CC)CCC2(C)C1(C)CCC2C(C)CCCC(C)C RRTBTJPVUGMUNR-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241001136860 Ficus tikoua Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- HVXLSFNCWWWDPA-UHFFFAOYSA-N Isocycloartenol Natural products C1CC(O)C(C)(C)C2C31CC13CCC3(C)C(C(CCCC(C)=C)C)CCC3(C)C1CC2 HVXLSFNCWWWDPA-UHFFFAOYSA-N 0.000 description 1
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 241001358279 Malaya Species 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241000266847 Mephitidae Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010051986 Pneumatosis Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- HXQRIQXPGMPSRW-UHZRDUGNSA-N Pollinastanol Natural products O[C@@H]1C[C@H]2[C@@]3([C@]4([C@H]([C@@]5(C)[C@@](C)([C@H]([C@H](CCCC(C)C)C)CC5)CC4)CC2)C3)CC1 HXQRIQXPGMPSRW-UHZRDUGNSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 description 1
- 241000748489 Smallanthus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 239000003225 biodiesel Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940017545 cinnamon bark Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- ONQRKEUAIJMULO-YBXTVTTCSA-N cycloartenol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@@]3(C)[C@@H]1CC2 ONQRKEUAIJMULO-YBXTVTTCSA-N 0.000 description 1
- YNBJLDSWFGUFRT-UHFFFAOYSA-N cycloartenol Natural products CC(CCC=C(C)C)C1CCC2(C)C1(C)CCC34CC35CCC(O)C(C)(C)C5CCC24C YNBJLDSWFGUFRT-UHFFFAOYSA-N 0.000 description 1
- FODTZLFLDFKIQH-UHFFFAOYSA-N cycloartenol trans-ferulate Natural products C1=C(O)C(OC)=CC(C=CC(=O)OC2C(C3CCC4C5(C)CCC(C5(C)CCC54CC53CC2)C(C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 108010046301 glucose peroxidase Proteins 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- OSELKOCHBMDKEJ-WGMIZEQOSA-N isofucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC/C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-WGMIZEQOSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 235000020245 plant milk Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- DXIHILNWDOYYCH-UHDJGPCESA-M sodium;(e)-3-phenylprop-2-enoate Chemical compound [Na+].[O-]C(=O)\C=C\C1=CC=CC=C1 DXIHILNWDOYYCH-UHDJGPCESA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000000152 swallowing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及药食同源类配方食品技术领域,公开了一种降糖、脂、血粘的纯天然植物压片糖果,按照质量百分比组分,包括油莎豆10‑18%、向天果75‑85%、肉桂2‑8%,0.5克/片,具有调节肠胃功能,控制血糖,降低血脂集多功能为一体。
Description
技术领域
本发明属于药食同源类配方食品技术领域,具体地说,涉及一种降糖、脂、 血粘的纯天然植物压片糖果及其制备方法。
背景技术
传统的糖果类食品只能满足人们补充营养以及食物多样化方面的需求,其 包含的营养物质往往只注重人体补充能量的需要。随着人们生活水平的提高, 人们越来越注重饮食对自身身体健康的影响,因此,具有功能性的糖果类食品 成了糖果类食品发展的新潮流。
功能性糖果能够促进人体健康、调节人体特定生理机能,对人体不会产生 不良反应,越来越受到人们的欢迎。功能性糖果与普通糖果都具有一般食品的 营养和感官享受两大特点,都具有糖果的基本工艺特征,其主要区别在于,功 能性糖果具有调节人体生理机能的第三大功能,它能在促进人体健康、突破亚 健康、预防疾病等方面起到重要作用。
中医药是中华民族的瑰宝,我们在继承发扬中医药优势的基础上,充分运 用现代科学技术,开发以中药为基础的相关产品如食品、保健品、化妆品、日 用品等是中医药创新发展的优先领域,以满足时代发展和人民群众日益增长的 医疗保健需求,鉴于此以中药材为原料的功能性压片糖果应用而生。
发明内容
本发明的目的在于克服现有的天然植物制品存在的问题,提供一种降糖、 脂、血粘的纯天然植物压片糖果,具有调节肠胃功能,控制血糖,降低血脂集 多功能为一体。
为了实现以上目的,本发明采用的技术方案是:
一种降糖、脂、血粘的纯天然植物压片糖果,由油莎豆、向天果、肉桂组 成。
为了进一步优化本发明,可优先选用以下技术方案:
优选的,上述材料按照质量百分比组分,包括油莎豆10-18%、向天果75-85%、 肉桂2-8%,0.5克/片。
优选的,上述材料按照质量百分比组分,包括油莎豆15%、向天果80%、肉 桂5%。
一种制备降糖、脂、血粘的纯天然植物压片糖果的方法,包括以下步骤:
步骤A:按照配方原料称取油莎豆、向天果、肉桂;
步骤B:粉碎,将上述原料按照配方比例,放置在冷冻超微粉碎机中,设置 粉碎参数为3500~4500转/min;
步骤C:装包,称取步骤B中粉碎混合后的成品,以10克/包标准进行封袋、 塑封。
一种使用降糖、脂、血粘的纯天然植物压片糖果的方法,用上述制得的压 片糖果,每日2~3次,每次2-3克。
本发明的有益效果是:
本产品的有益效果分析:本发明制剂配方科学合理,配方中将油莎豆、向天 果、肉桂按一定比例合理配伍,使各药物的功效产生协同的作用,互相促进, 使得产品具有健脾养胃、助消化,调节血糖,降低血脂的多重功效。其中:油 莎豆富含油脂,含量高达26%以上,其高油酸、高亚油酸和高棕榈酸,含大量VE、VC,不含胆固醇,极具抗氧化性,是优质的不干性食用油,不产生反式脂 肪酸,适合所有人群食用;向天果(学名Fructus SwieteniaMacrophylla), 属于楝科植物,盛产于南太平洋最洁净,受污染最少的所罗门群岛,产量稀少, 较为珍贵。主要用于调节糖尿病、高血压、高血脂、内分泌失调等症,长期服 用有改善身体机能,提高身体免疫功能、扶正固体,活化细胞、预防老化、延 缓衰老,对人体大有益处;中药材肉桂的作用(药理学):本产品含挥发油,油 中主要成分为桂皮醛、桂皮酸、甲酸八角茴香酯等。除此之外尚带有营养元素, 在其中锌成分较高。具备抗溃疡、止痛、镇定、抗惊厥、退热、抗心肌缺血、 抗血小板聚集、升白细胞、抗放射性、抑菌等功效。经过药理试验证实,通过 上述药物共同协作后本压片糖果可调理肠胃,助消化,增强肠胃运动功能,同时具有提高糖耐量水平,降低血脂的功效,且安全有效,毒副作用小。本发明 的压片糖果还具有保存期长、产品便于携带、方便服用等优点,且制备工艺简 单,便于工厂批量化生产。
具体实施方式
油莎豆(又称虎坚果)原产地是非洲及地中海沿岸国家,属禾本科一年生植 物,适应性极强中国引进并且种植在黑龙江,北京、河北、湖南、山东、四川 等地。它是一种优质、高产、综合利用价值很高的油、粮多用新型作物,又名 汕莎草,也是美化、绿化环境的观赏植物。该品种适应性强,产量高,一般亩 产鲜豆1000Kg,干豆500kg,种1亩油莎豆相当于7~10亩油菜。叶子针形细 而长,株高1米左右,生长旺盛,分蘖力强,地下结块茎。
油莎豆的营养成分含量丰富,包括油脂、淀粉、糖、蛋白质、纤维素、维 生素及多种矿物质。其中油脂、糖、淀粉、蛋白质和水分的含量分别为26.5%, 23.35%,23.21%,8.00%,7.00%。据测定,每100克油莎豆中含386卡路里(1615KJ) 能量。油莎豆因营养含量丰富,在非洲,欧洲,澳洲,美国,加拿大,日本, 中国等地被广泛的用于粮食、食用油、面粉、植物奶、休闲食品、航天、化妆 品、生物柴油等领域。因此,它被称为“神奇的豆子”。
油莎豆油的独有好处:油莎豆富含油脂,含量高达26%以上,其高油酸、高 亚油酸和高棕榈酸,含大量VE、VC,不含胆固醇,极具抗氧化性,是优质的不 干性食用油,不产生反式脂肪酸,适合所有人群食用。且可用于高温炸制食品, 是人造氢化油的优质替代品。特别适应人群:男性:独有的油脂酸与精氨酸帮 助减少胆固醇,预防动脉硬化、脂肪肝等疾病。女性:丰富的可溶性纤维与碳 水化合物促进肠道活动实现排毒养颜功效。孕婴:高能量物质与铁锌等多种微 量元素帮助提高儿童消化能力,视力,智力发育,促进生长健康发育。
油莎豆的药用价值:《新华本草纲要》记载,油莎豆含油量18一36%,主含 淀粉、糖、蛋白质和氨基酸。油中不皂化物含7一胆甾烯醇、菜油甾醇、豆甾 醇或豆甾烷醇、B一谷甾醇、24一亚甲基一Δ7一胆甾醇、Δ5一燕麦甾醇、环 阿屯烷醇、24一亚甲基环阿屯烷醇。油脂中脂肪酸有日桂酸、肉豆蔻酸、棕榈 酸、硬脂酸、油酸、花生烯酸(dedoleicacid)山萮酸、木焦油酸等。具有“疏 肝行气、健脾和胃”的功效,用于肝郁所致的胁痛、胸闷;脾胃气滞所致的脘 腹胀满、嗳气呕恶、胃痛纳呆、脾虚食少,食积停滞,消化不良等。
向天果(学名Fructus Swietenia Macrophylla),属于楝科植物,盛产于 南太平洋最洁净,受污染最少的所罗门群岛,产量稀少,较为珍贵。主要用于 调节糖尿病、高血压、高血脂、内分泌失调等症,长期服用有改善身体机能, 提高身体免疫功能、扶正固体,活化细胞、预防老化、延缓衰老,对人体大有 益处。向天果性凉,解热、收敛,种仁味苦、涩,无任何副作用,为非常难得 的一种植物。向天果其种子主治:糖尿病、高血压。用法:干种子9克煎服。 《马来西亚草药目录》中记载:向天果树皮味苦涩、性凉可解热、收敛、种仁 强壮。用法:糖尿病、体虚者,用鲜种子6—19克(敢_}并26克),水煎服,或 研粉入胶囊服。向天果被誉为”植物之后”,其保健效益在所罗门群岛早已世 代相传,当地所罗门群岛居民服用向天果的历史已逾千年,用于治疗糖尿病、 高血压、过敏性疾病、内分泌失调等。据统计,当地人的糖尿病、高血压的发 病率远低于世界其他地区,这与其长期食用向天果密切相关。可惜由于缺乏现 代科学的科研与提练,多年来向天果实所蕴含的价值未被全部开发及广泛利用。
20世纪末,凯尔国际联合马来亚医学院大学教授Dr.Mustafa Ali Mohd和 驻沙地阿拉伯药剂系博士Dr.OssamaArafat对向天果进行深入科研实验研究; 研究结果显示,向天果富含以下三大活性成分,拥有高效地改善高血压和血糖 水平的功能。①皂甙:降低血糖改善症状;降低胆固醇,降血脂抑制肥胖;(皂 甙可抑制胆固醇在肠道的吸收,能降低血浆胆固醇,改善脂质代谢,并可预防 因高脂肪膳食所造成的高血脂症。);降低血小板凝聚,避免形成血栓;(能 调节机体的溶血系统,抑制血小板聚集,改善血凝,减少血栓形成,增加心脑 血流量,提高机体抗缺氧功能。);改善血凝状况避免心肌梗塞;增强抗病力 及增进体力;(增加白血环数量加吞噬细胞的吞噬能力。);提高免疫功能; 抗癌抑制肿瘤。②黄酮类:有效促进血液循环;预防脑血管阻塞引起中风、预 防老人痴呆症;能降低脂肪在血管壁上的累积;能改善或降低血中胆固醇含量;
能促使体内防止各组织发炎的自然抗体生成;能阻挠动脉硬化的形成;能清 除体内过多的自由基;具有防止体内氧化作用的功能。③异黄酮:天然植物雌 激素:调理女性生理时钟:舒缓更年期症状:预防骨骼疏松症:此外,向天果 内还含有多种天然蛋白质、维生素A、B1、B3、B6、D、E及叶酸、铁、钾等人 体必要营养成份;当然,以上三种活性成份个别都能在不同的药用植物中获取, 例如:皂甙可以在久负盛名的人参中找到,而黄酮化合物也可以从国际知名的 银杏中获取。不过,在同一植物中同时获取这两种成份,且在量的比例合适者 的例子却不多见。这三种活性成份在保健上的应用范围已相当广阔,向来备受 医学家们的重视,如今发现竟同在一植物体内善巧配搭,功效必有另番境界。 再配合向天果中原有的其他营养成份,更能发挥改善血液循环、清血、调补及 提升免疫力等作用。向天果不仅有直接降血糖作用,而且可以代替降糖药物, 在血糖维持正常且稳定的情况下,便可以停止服用降糖药物,只需吃向天果就 能稳固血糖,它没有副作用,能预防或减少并发症。向天果本身具有的保肝作 用也可以减轻或防止一些口服降血糖药物对肝脏的损害。向天果降血糖的原理 是它能调整身体代谢功能,使自身的胰岛素得以“复活”而充分发挥作用,这样就可使血糖能够重新被机体组织细胞所摄取和利用,使血糖下降,达到长期 稳定和全面地控制血糖的目的,使人体可长久享用自身分泌的胰岛素,以分解 血糖。调节血压;向天果用于治疗高血压,能降低和平稳血压,预防脑血管阻 塞引起中风、预防老人痴呆症;同时增进血液循环和防止血管阻塞,能够帮助 预防心脏病和中风。向天果对糖尿病人和高血压病人有非常大的帮助,长期服 用向天果不仅能降血糖血压、平稳血糖血压,还不会出现副作用,起到防治并 发症的作用。降低胆固醇;向天果可抑制胆固醇在肠道的吸收,能降低血浆胆 固醇,改善脂肪代谢,并可预防因高脂肪膳食所造成的高血脂症,起到降低血 脂和胆固醇的作用。调节人体机能;向天果有助于调节人体各器官之间的内环 境平衡,保障每个细胞的正常活动,促进微循环系统的血液流量,提高人体免 疫能力,确保人体器官组织功能操作健全,能增进血液循环和防止血管阻塞, 能够帮助预防心脏病和中风。对治疗糖尿病,血压高、过敏性疾病、内分泌失 调等有非常显著的功效;向天果还具有养生作用,对于壮阳益精,消除疲劳,增 强体力,排毒,修复组织,提高受孕率,扶正固体,活化细胞,美艳养颜,预防 老化,强胃健肺,解酒保肝,益血补脉,健睥止泻,清毒排毒,调节血糖,养心安 神等神奇功效。
肉桂的性能:补火温补肾阳,祛寒止疼,温经通脉。
1)补火温补肾阳,根据补命门穴之火,用以温助全身气血,也用以阳虚诸 证,常与禄特科技相须会用,禄特科技与肉桂粉在补火温补肾阳层面的差别: 心肾气血衰落时,禄特科技有显著的功效,肉桂粉无,故亡阳证用禄特科技;肉 桂粉善于生火归原(阴虚火旺造成的虚阳上泛,出現真寒假热的补阳功效),但 禄特科技也一样有不错实际效果。用以脾肾虚,命门火衰及脾肾阳衰证,肉桂 粉辛热纯阳,能补命门穴之火,易阳消阴,为治下元虚冷的要药。常与禄特科 技、熟地、山茱萸等温补虚药同用,如桂附八味丸。脾肾阳衰者,配禄特科技、 炮姜、白术茯苓等以清补脾肾。若下元虚冷,虚阳上调,见上热下寒者,能用 以引火归元。
2)祛寒止疼,包含彭中,与禄特科技比,禄特科技还主要表现出袪风湿, 故风湿病痹证常见,肉桂粉和桂枝一样,善于入血分,能温通血脉,故许多寒 凝血瘀的聚瑞用肉桂粉通调经络,肉桂粉强过桂枝,肉桂粉可温运气血,鼓励 血气的生长发育,补气补血的聚瑞,天赋加点肉桂粉,有益于滋阴养血药阳生 阴长,有利于补血补气。用以脘腹冷痛,湿寒痹痛,腰痛,及其血分有寒之瘀 滞肝郁肾虚、经痛等。肉桂粉既能散沉寒,又能通血脉,不管寒凝气滞血瘀, 或寒凝血瘀引发的痛证均可运用。可单单使用研粉服用,或搭配其他祛寒止疼 药;血分有寒,血行不畅者,并搭配川芎、羌活等活血化瘀通脉的药品
3)通调血脉,用以阴疽及血气阴虚内热、痈疮脓成不溃,或溃后久不收敛 性等外科疾病。用之能散寒温阳,顺畅血气。阴疽,可配熟地、鹿角胶、麻黄 等,如阳和汤。气血不足者,配黄芩、川芎等,如托里黄芪汤。
中药材肉桂的作用(药理学):本产品含挥发油,油中主要成分为桂皮醛、桂 皮酸、甲酸八角茴香酯等。除此之外尚带有营养元素,在其中锌成分较高。具 备抗溃疡、止痛、镇定、抗惊厥、退热、抗心肌缺血、抗血小板聚集、升白细 胞、抗放射性、抑菌等功效。
1)本产品含挥发油,称之为八角茴香油或肉桂油,油中主要成分为桂皮醛、 甲酸八角茴香酯、甲酸丙苯酯等;除此之外,尚含粘液质、鞣质等。本产品水煎 剂有软化血管、推动血液循环、提升冠状动脉及脑血容量,使血管摩擦阻力降 低,能显著降低肾上腺激素再造高血压大白鼠的血压和尿醛固酮量,提升排尿, 显着提高纹状体及下丘脑垂体的脑啡肽成分,能大大提高胸主动脉子宫内膜的 高血压危害。在身体之外,其乙醇提取液及桂皮醛有抗血小板凝结、抗凝血酶 功效。八角茴香油、桂皮醛、肉桂酸钠具备止痛、镇定、退热、抗惊厥等功效。 桂皮醛及八角茴香酸钠可使家兔的白细胞计数提升。八角茴香油对胃黏膜有缓 解的刺激效果,并根据刺激性嗅觉反射地推动胃功能,能推动肠健身运动,使 消化系统代谢提升,提高消化吸收功能,清除消化系统积气,减轻胃肠痉挛性 疼痛。肉桂粉水提物能抑止单核心巨噬细胞系统的吞食作用,抑止小羊血细胞 过敏反应小白鼠的抗原造成量,能减少幼鼠脾重,能抑止补体免疫力溶血反应 (身体之外)。桂皮醛及八角茴香酸钠可使家兔的白细胞计数提升。八角茴香油 可造成孑宫血肿。八角茴香油对革兰氏阳性及阴性菌有抑制效果。八角茴香的 医用乙醚、醇及水浸出液对多种多样高致病细菌有一定的抑制效果。
2)肉桂粉中药材有企边桂、板桂、桂通、桂心等多种多样。企边桂,为剥 取生长发育十多年的肉桂树树杆皮,经夹在木质凸凹板内晾干而成,呈长块状。 板桂,别称桂楠,为剥取老年人肉桂粉树杆皮,夹在桂夹内,晒至七成干时取 下,晾干而成,呈板块状。桂通别称官桂、桂尔通、条桂、筒桂,为种植5~6 年肉桂粉幼树干性皮肤或粗枝皮,撕下后晒1~2天,叠成圆柱状晾干而成,呈 圆柱形或半槽状。桂心,即生产加工中检下的装饰条,去除栓皮者。企边桂香 味较浓郁,油溶性大,品质为好。
实施例1:
一种降糖、脂、血粘的纯天然植物压片糖果,由油莎豆、向天果、肉桂组 成,材料按照质量百分比组分,包括油莎豆12%、向天果83%、肉桂5%,0.5克 /片。
实施例2:
一种降糖、脂、血粘的纯天然植物压片糖果,由油莎豆、向天果、肉桂组 成,材料按照质量百分比组分,包括油莎豆15%、向天果80%、肉桂5%,0.5克 /片。
实施例3:
一种降糖、脂、血粘的纯天然植物压片糖果,由油莎豆、向天果、肉桂组 成,材料按照质量百分比组分,包括油莎豆18%、向天果77%、肉桂5%,0.5克 /片。
一种制备降糖、脂、血粘的纯天然植物压片糖果的方法,包括以下步骤:
步骤A:按照配方原料称取油莎豆、向天果、肉桂;
步骤B:粉碎,将上述原料按照配方比例,放置在冷冻超微粉碎机中,设置 粉碎参数为3500~4500转/min,制得混合物料;
步骤C:制粒混合物料经制粒机制粒,去除非颗粒制品,留取颗粒制品;
步骤D:干燥将制好的颗粒制品倒入干燥机内,真空干燥,干燥温度为 60-80℃,干燥时间30-60分钟,得干燥颗粒;
步骤E:整粒压片干燥颗粒加入多向旋转混合机中,混合20-40分钟,之 后经压片机压片处理,制得压片糖果。
为验证本发明的降血糖组合物产品的功效性和安全性,发明人选用实施例 2、实施例3做了小鼠试验。
1.材料与方法
1.1实验动物与材料
昆明种小鼠220只,10月龄,雌雄各半,体重30-35g。所用组合物的原料 配比为实施例2和实施例3中的配比。
1.2实验方法
1.2.1糖尿病小鼠模型的制备与分组
SPF级小鼠,雄性,由有生产许可证号的实验动物中心提供 SCXK(军)2012-0004。18g~20g,220只,雌雄各半,随机选取20只小鼠用于空 白组,剩下的200只按每千克体重尾腹腔注射150mg四氧嘧啶(配制成3重量份 的水溶液,现配现用)。在注射后的第3天,禁食12h后进行眼眶静脉采血0.05mL, 在8000r/min转速离心10min,离心后取15μL血清,用血糖试剂盒测定小鼠血 糖。选取空腹血糖高于10mmol/L者(即糖尿病小鼠)用于实验。
将糖尿病小鼠随机分成5组,每组2个重复,分别为糖尿病模型组、格列 本脲阳性对照组、库拉索芦荟凝胶粉对照组、苦瓜粉对照组、实施例1组合物 组和实施例2组合物组,其中格列本脲阳性对照组灌胃格列本脲20mg/kg体重 /d;库拉索芦荟凝胶粉对照组、苦瓜对照组分别作为对照组1、对照组2、对照 组3,实施例,2组合物组和实施例3组合物组使用本发明实施例2和实施例3 的降糖组合物的配方。
1.2.2降糖实验
空白组和糖尿病模型组分别灌胃蒸馏水80mg/kg体重/d;格列本脲阳性对 照组灌胃格列本脲20mg/kg体重/d;库拉索芦荟凝胶粉对照组、苦瓜对照组、 实施例1组合物组和实施例2组合物组分别灌胃相应的成分200mg/kg体重/d, 连续进行6周,每两周进行称重并采血测血糖,采血前禁食12h。
1.2.3血糖的测定
采用葡萄糖-过氧化物酶法测定。计算公式为:血糖=Au/As×5.55mmol/L 式中:Au为样品的吸光度;As为葡萄糖标准品的吸光度;5.55位常数。
1.2.4统计方法
采用DPS统计软件进行差异显著性t-检验,各项指标以平均数±标准差表 示。
2结果与分析
实验结果见表1。
经过上述数据分析可知,可以看到灌胃4周后和6周后,格列本脲对照组、 库拉索芦荟凝胶粉对照组、苦瓜对照组、实施例1组合物组和实施例2组合物 组对小鼠餐后空腹血糖值都有很好的降低作用,其中库拉索芦荟凝胶粉对照组 和苦瓜对照组之间差异不明显,但实施例2组合物组和实施例3组合物组与上 述两个对照组之间差异极显著,并且它们与格列本脲对照组之间的差异不显著, 这就说明本发明的降血糖组合物的降糖效果要明显优于单一的库拉索芦荟凝胶 粉和苦瓜粉,而与降糖药物格列本脲的效果接近,并且实施例3的降糖效果更 优。但相比格列本脲,本组合物无毒副作用,因此具有很好的价值。
注:小写字母不同表示差异显著(P<0.05);大写字母不同表示差异极显著 (P<0.01)。
Claims (5)
1.一种降糖、脂、血粘的纯天然植物压片糖果,其特征在于,由油莎豆、向天果、肉桂组成。
2.根据权利要求1所述的一种降糖、脂、血粘的纯天然植物压片糖果,其特征在于:材料按照质量百分比组分,包括油莎豆10-18%、向天果75-85%、肉桂2-8%,0.5克/片。
3.根据权利要求2所述的一种降糖、脂、血粘的纯天然植物压片糖果,其特征在于:材料按照质量百分比组分,包括油莎豆15%、向天果80%、肉桂5%,。
4.一种制备权利要求1所述的降糖、脂、血粘的纯天然植物压片糖果的方法,其特征在于,包括以下步骤:
步骤A:按照配方原料称取油莎豆、向天果、肉桂;
步骤B:粉碎,将上述原料按照配方比例,放置在冷冻超微粉碎机中,设置粉碎参数为3500~4500转/min,制得混合物料;
步骤C:制粒混合物料经制粒机制粒,去除非颗粒制品,留取颗粒制品;
步骤D:干燥将制好的颗粒制品倒入干燥机内,真空干燥,干燥温度为60-80℃,干燥时间30-60分钟,得干燥颗粒;
步骤E:整粒压片干燥颗粒加入多向旋转混合机中,混合20-40分钟,之后经压片机压片处理,制得压片糖果。
5.一种使用权利要求1所述的降糖、脂、血粘的纯天然植物压片糖果的方法,其特征在于,用上述制得的压片糖果,每日2~3次,每次2-3克。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110530298.7A CN113142573A (zh) | 2021-05-14 | 2021-05-14 | 一种降糖、脂、血粘的纯天然植物压片糖果及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110530298.7A CN113142573A (zh) | 2021-05-14 | 2021-05-14 | 一种降糖、脂、血粘的纯天然植物压片糖果及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113142573A true CN113142573A (zh) | 2021-07-23 |
Family
ID=76876115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110530298.7A Pending CN113142573A (zh) | 2021-05-14 | 2021-05-14 | 一种降糖、脂、血粘的纯天然植物压片糖果及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113142573A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0823922A (ja) * | 1994-07-15 | 1996-01-30 | Nikken Food Kk | 錠菓及びその製造方法 |
CN101731621A (zh) * | 2010-01-17 | 2010-06-16 | 李国平 | 一种油莎豆保健食品与制作方法 |
CN103155967A (zh) * | 2011-12-14 | 2013-06-19 | 全龙浩 | 油莎豆饼干及其制备方法 |
CN107183295A (zh) * | 2017-06-20 | 2017-09-22 | 慧谷生命科技湖北有限公司 | 一种血钻野燕麦压片糖果 |
CN108175098A (zh) * | 2017-11-30 | 2018-06-19 | 慈中华 | 润肺的营养组合物及其制备方法 |
CN108391804A (zh) * | 2018-05-02 | 2018-08-14 | 西南复星(北京)科技有限公司 | 一种油莎豆口嚼片、糖果及其制备方法 |
CN108497392A (zh) * | 2018-05-29 | 2018-09-07 | 闫峻峰 | 一种预防高血糖高血压的食品 |
CN110140795A (zh) * | 2019-06-24 | 2019-08-20 | 中源宝鉴(厦门)生物科技有限公司 | 一种具有化脂功能的压片糖果及其制备方法 |
CN111264869A (zh) * | 2020-04-08 | 2020-06-12 | 孙运河 | 降低血糖的食品及其制作方法 |
-
2021
- 2021-05-14 CN CN202110530298.7A patent/CN113142573A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0823922A (ja) * | 1994-07-15 | 1996-01-30 | Nikken Food Kk | 錠菓及びその製造方法 |
CN101731621A (zh) * | 2010-01-17 | 2010-06-16 | 李国平 | 一种油莎豆保健食品与制作方法 |
CN103155967A (zh) * | 2011-12-14 | 2013-06-19 | 全龙浩 | 油莎豆饼干及其制备方法 |
CN107183295A (zh) * | 2017-06-20 | 2017-09-22 | 慧谷生命科技湖北有限公司 | 一种血钻野燕麦压片糖果 |
CN108175098A (zh) * | 2017-11-30 | 2018-06-19 | 慈中华 | 润肺的营养组合物及其制备方法 |
CN108391804A (zh) * | 2018-05-02 | 2018-08-14 | 西南复星(北京)科技有限公司 | 一种油莎豆口嚼片、糖果及其制备方法 |
CN108497392A (zh) * | 2018-05-29 | 2018-09-07 | 闫峻峰 | 一种预防高血糖高血压的食品 |
CN110140795A (zh) * | 2019-06-24 | 2019-08-20 | 中源宝鉴(厦门)生物科技有限公司 | 一种具有化脂功能的压片糖果及其制备方法 |
CN111264869A (zh) * | 2020-04-08 | 2020-06-12 | 孙运河 | 降低血糖的食品及其制作方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103141709B (zh) | 一种鲤鱼饲料及其制备方法 | |
CN104873763A (zh) | 一种调理气虚体质的保健品 | |
CN110447902B (zh) | 一种具有减肥功效的组合物 | |
CN102755596A (zh) | 一种治疗痰湿型乳腺增生的中药及制备方法 | |
CN102551046B (zh) | 一种天然减肥保健组合物及其应用 | |
CN104206594A (zh) | 一种降压降脂的桑寄生保健茶及其制备方法 | |
CN104905267A (zh) | 一种决明子降血脂保健口服液及其制备方法 | |
CN111919982A (zh) | 天然植物解酒饮料及其制备方法 | |
CN104606663B (zh) | 一种促进产后恢复的中药及其制备方法 | |
CN103239667B (zh) | 一种治疗家畜口蹄疫的中药 | |
CN106472684A (zh) | 一种乳制品 | |
CN108186966A (zh) | 一种预防或改善老年痴呆症的组合物及其应用 | |
CN110574916A (zh) | 一种具有减脂和通便功效的营养代餐产品及其制备方法 | |
CN113952419A (zh) | 一种用于慢性肾功能衰竭的药物组合物及制备方法和应用 | |
CN113142573A (zh) | 一种降糖、脂、血粘的纯天然植物压片糖果及其制备方法 | |
CN107362301B (zh) | 香苓开胃颗粒 | |
CN102599312B (zh) | 低聚糖三七甜茶及其制备方法 | |
CN101991773B (zh) | 一种枇杷肉提炼成枇杷膏及其制备方法 | |
CN106472681A (zh) | 一种乳制品 | |
CN103877513A (zh) | 一种具有降血脂功效的中药复方组合物及其应用 | |
CN107737250A (zh) | 一种高血压中药组合物及其制备方法 | |
CN111388563B (zh) | 一种用于预防新生儿母乳性黄疸的组合物及其制备方法和应用 | |
CN105062820A (zh) | 一种夏季本草健身酒及其制备方法 | |
CN105582379A (zh) | 一种治疗肝胃不和的中药组合物及其制备方法 | |
CN106177480A (zh) | 一种包含青钱柳叶和石斛的降血糖保健组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210723 |